Renalytix (RNLX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

RNLX Stock Forecast

Renalytix stock forecast is as follows: an average price target of $2.00 (represents a 1231.56% upside from RNLX’s last price of $0.15) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

RNLX Price Target

The average price target for Renalytix (RNLX) is $2.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential 1231.56% upside from RNLX's last price of $0.15.

RNLX Analyst Ratings

Buy

According to 2 Wall Street analysts, Renalytix's rating consensus is 'Buy'. The analyst rating breakdown for RNLX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Renalytix Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 16, 2024	Mark Massaro	BTIG	$2.00	$0.57	252.73%	1231.56%
Jul 01, 2022	Mark Massaro	BTIG	$5.00	$2.45	104.08%	3228.89%

Row per page

Go to

The latest Renalytix stock forecast, released on May 16, 2024 by Mark Massaro from BTIG, set a price target of $2.00, which represents a 252.73% increase from the stock price at the time of the forecast ($0.57), and a 1231.56% increase from RNLX last price ($0.15).

Renalytix Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$2.00
Last Closing Price	$0.15	$0.15	$0.15
Upside/Downside	-100.00%	-100.00%	1231.56%

In the current month, the average price target of Renalytix stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Renalytix's last price of $0.15. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jun 17, 2024	H.C. Wainwright	Buy	Buy	Hold
May 16, 2024	BTIG	Buy	Buy	Hold

Row per page

Go to

Renalytix's last stock rating was published by H.C. Wainwright on Jun 17, 2024. The company gave RNLX a "Buy" rating, the same as its previous rate.

Renalytix Financial Forecast

Renalytix Revenue Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Revenue	-	-	-	-	-	-	$709.00K	$459.00K	-	$724.00K	$1.19M	$969.00K	$831.00K	$812.00K	$845.00K	$482.00K
Avg Forecast	$1.30M	$1.20M	$1.00M	$900.00K	$775.00K	$1.09M	$763.50K	$715.00K	$823.33K	$1.48M	$1.28M	$1.10M	$806.67K	$2.02M	$550.00K	$2.30M
High Forecast	$1.30M	$1.20M	$1.00M	$900.00K	$775.00K	$1.09M	$763.50K	$715.00K	$823.33K	$1.48M	$1.28M	$1.10M	$806.67K	$2.02M	$550.00K	$2.30M
Low Forecast	$1.30M	$1.20M	$1.00M	$900.00K	$775.00K	$1.09M	$763.50K	$715.00K	$823.33K	$1.48M	$1.28M	$1.10M	$806.67K	$2.02M	$550.00K	$2.30M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	0.93%	0.64%	-	0.49%	0.93%	0.88%	1.03%	0.40%	1.54%	0.21%

Renalytix's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.09M, with a low forecast of $1.09M, and a high forecast of $1.09M. RNLX's average Quarter revenue forecast represents a 53.74% increase compared to the company's last Quarter revenue of $709.00K (Dec 23).

Renalytix EBITDA Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	$-8.64M	$-7.11M	-	$-9.88M	$-8.73M	$-9.53M	$-9.35M	$-11.83M	$-15.21M	$-9.99M
Avg Forecast	$-780.00K	$-720.00K	$-600.00K	$-540.00K	$-465.00K	$-654.00K	$-458.10K	$-429.00K	$-494.00K	$-888.00K	$-770.00K	$-660.00K	$-484.00K	$-1.21M	$-330.00K	$-1.38M
High Forecast	$-780.00K	$-720.00K	$-600.00K	$-540.00K	$-465.00K	$-654.00K	$-458.10K	$-429.00K	$-494.00K	$-888.00K	$-770.00K	$-660.00K	$-484.00K	$-1.21M	$-330.00K	$-1.38M
Low Forecast	$-780.00K	$-720.00K	$-600.00K	$-540.00K	$-465.00K	$-654.00K	$-458.10K	$-429.00K	$-494.00K	$-888.00K	$-770.00K	$-660.00K	$-484.00K	$-1.21M	$-330.00K	$-1.38M
Surprise %	-	-	-	-	-	-	18.86%	16.57%	-	11.12%	11.34%	14.43%	19.32%	9.75%	46.11%	7.24%

undefined analysts predict RNLX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Renalytix's previous annual EBITDA (undefined) of $NaN.

Renalytix Net Income Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	$-8.48M	$-10.15M	-	$-12.11M	$-12.03M	$-11.95M	$-16.61M	$-14.85M	$-16.86M	$-8.40M
Avg Forecast	$-4.14M	$-4.14M	$-4.14M	$-5.53M	$-7.60M	$-12.43M	$-12.47M	$-14.51M	$-16.28M	$-15.49M	$-18.88M	$-16.43M	$-24.87M	$-23.83M	$-22.11M	$-18.42M
High Forecast	$-4.14M	$-4.14M	$-4.14M	$-5.53M	$-7.60M	$-12.43M	$-12.47M	$-14.51M	$-16.28M	$-15.49M	$-18.88M	$-16.43M	$-24.87M	$-23.83M	$-22.11M	$-18.42M
Low Forecast	$-4.14M	$-4.14M	$-4.14M	$-5.53M	$-7.60M	$-12.43M	$-12.47M	$-14.51M	$-16.28M	$-15.49M	$-18.88M	$-16.43M	$-24.87M	$-23.83M	$-22.11M	$-18.42M
Surprise %	-	-	-	-	-	-	0.68%	0.70%	-	0.78%	0.64%	0.73%	0.67%	0.62%	0.76%	0.46%

Renalytix's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RNLX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Renalytix SG&A Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	$5.34M	$6.06M	-	$7.09M	$6.81M	$8.25M	$29.28M	$10.81M	$10.07M	$8.13M
Avg Forecast	$8.39M	$7.74M	$6.45M	$5.81M	$5.00M	$7.03M	$4.93M	$4.61M	$5.31M	$9.55M	$8.28M	$7.10M	$5.20M	$13.05M	$3.55M	$14.84M
High Forecast	$8.39M	$7.74M	$6.45M	$5.81M	$5.00M	$7.03M	$4.93M	$4.61M	$5.31M	$9.55M	$8.28M	$7.10M	$5.20M	$13.05M	$3.55M	$14.84M
Low Forecast	$8.39M	$7.74M	$6.45M	$5.81M	$5.00M	$7.03M	$4.93M	$4.61M	$5.31M	$9.55M	$8.28M	$7.10M	$5.20M	$13.05M	$3.55M	$14.84M
Surprise %	-	-	-	-	-	-	1.08%	1.31%	-	0.74%	0.82%	1.16%	5.63%	0.83%	2.84%	0.55%

Renalytix's average Quarter SG&A projection for Mar 24 is $7.03M, based on 1 Wall Street analysts, with a range of $7.03M to $7.03M. The forecast indicates a 31.71% rise compared to RNLX last annual SG&A of $5.34M (Dec 23).

Renalytix EPS Forecast

	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	$-0.00	$-0.21	-	$-0.28	$-0.32	$-0.32	$-0.46	$-0.41	$-0.47	$-0.23
Avg Forecast	$-0.03	$-0.03	$-0.03	$-0.04	$-0.06	$-0.09	$-0.09	$-0.10	$-0.12	$-0.11	$-0.14	$-0.12	$-0.18	$-0.17	$-0.16	$-0.13
High Forecast	$-0.03	$-0.03	$-0.03	$-0.04	$-0.06	$-0.09	$-0.09	$-0.10	$-0.12	$-0.11	$-0.14	$-0.12	$-0.18	$-0.17	$-0.16	$-0.13
Low Forecast	$-0.03	$-0.03	$-0.03	$-0.04	$-0.06	$-0.09	$-0.09	$-0.10	$-0.12	$-0.11	$-0.14	$-0.12	$-0.18	$-0.17	$-0.16	$-0.13
Surprise %	-	-	-	-	-	-	0.00%	2.00%	-	2.50%	2.34%	2.69%	2.56%	2.38%	2.94%	1.73%

According to undefined Wall Street analysts, Renalytix's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RNLX previous annual EPS of $NaN (undefined).

Renalytix Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
RNLX	Renalytix	$0.21	$2.00	852.38%	Buy
AKLI	Akili	$0.43	$3.25	655.81%	Buy
HCAT	Health Catalyst	$7.53	$29.25	288.45%	Buy
FORA	Forian	$2.03	$4.50	121.67%	Buy
PGNY	Progyny	$13.90	$25.29	81.94%	Hold
AUGX	Augmedix	$2.35	$2.67	13.62%	Hold
HQY	HealthEquity	$102.40	$97.00	-5.27%	Buy
HSTM	HealthStream	$31.31	$29.00	-7.38%	Buy

RNLX Forecast FAQ

Is Renalytix a good buy?

Yes, according to 2 Wall Street analysts, Renalytix (RNLX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of RNLX's total ratings.

What is RNLX's price target?

Renalytix (RNLX) average price target is $2 with a range of $2 to $2, implying a 1231.56% from its last price of $0.15. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Renalytix stock go up soon?

According to Wall Street analysts' prediction for RNLX stock, the company can go up by 1231.56% (from the last price of $0.15 to the average price target of $2), up by 1231.56% based on the highest stock price target, and up by 1231.56% based on the lowest stock price target.

Can Renalytix stock reach $0?

RNLX's average twelve months analyst stock price target of $2 supports the claim that Renalytix can reach $0 in the near future.

What are Renalytix's analysts' financial forecasts?

Renalytix's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $3.34M (high $3.34M, low $3.34M), average EBITDA is $-2.006M (high $-2.006M, low $-2.006M), average net income is $-47.009M (high $-47.009M, low $-47.009M), average SG&A $21.57M (high $21.57M, low $21.57M), and average EPS is $-0.34 (high $-0.34, low $-0.34). RNLX's analysts financial forecasts for the fiscal year (Jun 2025) are as follows: average revenue is $4.4M (high $4.4M, low $4.4M), average EBITDA is $-2.64M (high $-2.64M, low $-2.64M), average net income is $-17.961M (high $-17.961M, low $-17.961M), average SG&A $28.39M (high $28.39M, low $28.39M), and average EPS is $-0.13 (high $-0.13, low $-0.13).

Did the RNLX's actual financial results beat the analysts' financial forecasts?

Based on Renalytix's last annual report (Jun 2022), the company's revenue was $2.97M, which missed the average analysts forecast of $5.68M by -47.70%. Apple's EBITDA was $-45.111M, beating the average prediction of $-3.408M by 1223.87%. The company's net income was $-56.732M, missing the average estimation of $-89.235M by -36.42%. Apple's SG&A was $12.95M, missing the average forecast of $36.64M by -64.65%. Lastly, the company's EPS was $-1.56, beating the average prediction of $-0.646 by 141.53%. In terms of the last quarterly report (Dec 2023), Renalytix's revenue was $709K, missing the average analysts' forecast of $763.5K by -7.14%. The company's EBITDA was $-8.641M, beating the average prediction of $-458K by 1786.27%. Renalytix's net income was $-8.485M, missing the average estimation of $-12.469M by -31.95%. The company's SG&A was $5.34M, beating the average forecast of $4.93M by 8.39%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.0902 by -99.89%